| Name | calcium channel (protein family or complex) |
|---|---|
| Synonyms | calcium channel |
| Name | warfarin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19445778 | Sarkees ML, Bavry AA: Acute coronary syndrome (unstable angina and non-ST elevation MI). Clin Evid. 2009 Jan 13;2009. pii: 0209. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: beta-blockers, calcium channel blockers, direct thrombin inhibitors, glycoprotein IIb/IIIa inhibitors (oral or intravenous), (low molecular weight, unfractionated), nitrates, routine early cardiac catheterisation and revascularisation, statins, and warfarin. |
31(0,1,1,1) | Details |
| 18789548 | Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, Follath F, Swedberg K, Madeira H, Cleland JG: Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. Int J Cardiol. 2010 Jan 7;138(1):63-9. Epub 2008 Sep 11. On multivariable analysis the following provided independent prognostic information: increasing age (OR per SD=1.5, 95% CI 1.4-1.6), severe LVSD (1.8, 1.5-2.1), serum (1.2, 1.2-1.3), (0.9, 0.8-0.9), Hb (0.9, 0.8-0.9) and treatment with ACEI (0.5, 0.5-0.6), beta-blockers (0.7, 0.6-0.8), statins (0.6, 0.5-0.7), calcium channel blockers (0.7, 0.6-0.8), warfarin (0.5, 0.4-0.6), (1.7, 1.4-1.9), anti-platelet drugs (0.6, 0.5-0.6) and need for inotropes (5.5, 4.6-6.6). |
6(0,0,1,1) | Details |
| 18394447 | Allen Lapointe NM, Sun JL, Kaplan S, d'Almada P, Al-Khatib SM: Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. Am J Cardiol. 2008 Apr 15;101(8):1134-41. Epub 2008 Feb 7. Warfarin use was greater in the rhythm-control group compared with the rate-control group (adjusted OR 1.56, 95% CI 1.52 to 1.60), and warfarin use was greater with a CHADS (2) score > or =2 (unadjusted OR 1.21, 95% CI 1.19 to 1.24). Patients managed only with beta blockers, calcium channel blockers, or were categorized as receiving rate control. |
1(0,0,0,1) | Details |
| 19188572 | Gidal BE, French JA, Grossman P, Le Teuff G: Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology. 2009 Feb 3;72(5):419-25. RESULTS: Use of concomitant medications occurred in every age group and increased with age for both men and women (mean number of non-AEDs ranging from 2.41 to 7.67 in males aged 18-34 and 85+ years and from 4.04 to 7.05 in females aged 18-34 and 85+ years; p < 0.001 for age trend). beta-Hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitors (statins), calcium channel blockers (CCBs), and selective reuptake inhibitors (SSRIs) were the most commonly used non-AED medications with the potential for adverse drug interactions. Use of antipsychotics, tricyclic antidepressants, and warfarin was also noted in more than 10% of patients across different age groups. |
1(0,0,0,1) | Details |
| 19050195 | Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH: Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008 Dec 3;300(21):2514-26. Clinical equivalence was noted in 7 of 7 RCTs (100%) of beta-blockers, 10 of 11 RCTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers, 3 of 3 RCTs (100%) of antiplatelet agents, 2 of 2 RCTs (100%) of statins, 1 of 1 RCT (100%) of angiotensin-converting enzyme inhibitors, and 1 of 1 RCT (100%) of alpha-blockers. Among narrow therapeutic index drugs, clinical equivalence was reported in 1 of 1 RCT (100%) of class 1 antiarrhythmic agents and 5 of 5 RCTs (100%) of warfarin. |
1(0,0,0,1) | Details |
| 18690874 | Steiropoulos P, Trakada G, Bouros D: Current pharmacological treatment of pulmonary arterial hypertension. . Curr Clin Pharmacol. 2008 Jan;3(1):11-9. Conventional treatment is based on non-specific drugs (warfarin, diuretics). |
0(0,0,0,0) | Details |
| 18501274 | Winterkorn JM, Mack P, Eggenberger E: Transient visual loss in a 60-year-old man. Surv Ophthalmol. 2008 May-Jun;53(3):301-5. The patient was treated with warfarin, baby and a calcium channel blocker and has not had a recurrence of permanent visual loss in 17 years. |
0(0,0,0,0) | Details |
| 18708824 | Aronow WS: Treatment of atrial fibrillation and atrial flutter: Part II. Cardiol Rev. 2008 Sep-Oct;16(5):230-9. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective direct current or drug cardioversion of AF and continued for at least 4 weeks after maintenance of sinus rhythm. |
0(0,0,0,0) | Details |